KR980000447A - 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 - Google Patents
미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 Download PDFInfo
- Publication number
- KR980000447A KR980000447A KR1019970025307A KR19970025307A KR980000447A KR 980000447 A KR980000447 A KR 980000447A KR 1019970025307 A KR1019970025307 A KR 1019970025307A KR 19970025307 A KR19970025307 A KR 19970025307A KR 980000447 A KR980000447 A KR 980000447A
- Authority
- KR
- South Korea
- Prior art keywords
- mirtazapine
- composition
- ssris
- depression
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
본 발명은 미르타자핀, 선택적인 세로토닌 재이용 저해제(SSRI) 그리고 약학적 허용 보조제를 포함하는 약학 조성물에 관한 것이다. 특히 SSRI는 플루옥세틴(fluoxetin), 플루복사민(fluvoxamine), 시타로프람(citalopram), 세리클라민(cericlamine) 페목세틴(femoxetin), 세르트랄린(sertraline), 파록세틴(paroxetin), 이폭세틴(ifoxetine) 시아노도티에핀(cyanodothiepin) 및 리톡세틴(litoxetine)으로부터 선택된다. 우울증 환자를 치료하기 위해 이용될 수 있는 상기 조성물은 미르타자핀 또는 SSRI만으로 환자를 치료하는 것보다 더 적은 부작용을 가진다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (10)
- 미르타자핀 또는 그들의 약학적 허용염과 하나 또는 그 이상의 SSRI 또는 그들의 약학적 허용염을 포함하는 조성물.
- 제1항에 있어서, 상기 SSRI가 지멜딘, 플루옥세틴, 플루복사민, 시타로프람, 세리클라민, 페목세틴, 이폭세틴, 시아노도티에핀, 세르트랄린, 파록세틴, 및 리톡세틴으로부터 선택된 조성물.
- 제1항에 있어서, 미르타자핀과 플루옥세틴을 포함하는 조성물.
- 제1항 내지 제3항 중의 어느 한 항에 있어서, 우울증 치료 용도를 위한 조성물.
- 제1항 내지 제3항 중의 어느 한 항에 따른 조성물을, 그들을 위한 하나 또는 그 이상의 약학적 허용 담체와 결합하여 포함하는 약학 제제.
- 제1항 내지 제3항 중의 어느 한 항에 정의된 조성물 또는 제5항에 설명된 제제를 치료적으로 유효한 양으로 동물을 치료하는 것을 포함하는, 동물의 우울증 치료 방법.
- 최소의 부작용을 가지는 항우울증 활성을 가지는 약제 제조에서 미르타자핀과 하나 또는 그 이상의 SSRI의 용도.
- 우울증 치료를 위해 미르타자핀과 동시에 또는 순차적으로 투여하기 위한 약제 제조에서 하나 또는 그 이상의 SSRI의 용도.
- 우울증 치료를 위해 하나 또는 그 이상의 SSRI와 동시에 또는 순차적으로 투여하기 위한 약제 제조에서 미르타자핀의 용도.
- 하나 또는 그 이상의 투여 단위가 미르타자핀을 함유하고 하나 또는 그 이상의 다른 투여 단위가 SSRI, 바람직하게는 플루옥세틴을 함유하는, 분리된 투여 단위를 포함하는 패키지(package).※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96201703.4 | 1996-06-19 | ||
EP96201703 | 1996-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR980000447A true KR980000447A (ko) | 1998-03-30 |
KR100481254B1 KR100481254B1 (ko) | 2005-09-12 |
Family
ID=8224094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019970025307A KR100481254B1 (ko) | 1996-06-19 | 1997-06-18 | 미르타자핀과하나이상의선택적인세로토닌재흡수저해제를포함하는약학조성물 |
Country Status (25)
Country | Link |
---|---|
US (1) | US5977099A (ko) |
JP (2) | JP4925074B2 (ko) |
KR (1) | KR100481254B1 (ko) |
CN (1) | CN1132581C (ko) |
AR (1) | AR007609A1 (ko) |
AT (1) | ATE213159T1 (ko) |
AU (1) | AU727851B2 (ko) |
BR (1) | BR9703624A (ko) |
CA (1) | CA2208199C (ko) |
CZ (1) | CZ290691B6 (ko) |
DE (1) | DE69710390T2 (ko) |
DK (1) | DK0813873T3 (ko) |
ES (1) | ES2172744T3 (ko) |
HK (1) | HK1006081A1 (ko) |
HU (1) | HU225534B1 (ko) |
ID (1) | ID17051A (ko) |
IL (1) | IL121076A (ko) |
NO (1) | NO313177B1 (ko) |
NZ (1) | NZ328113A (ko) |
PL (1) | PL188520B1 (ko) |
PT (1) | PT813873E (ko) |
RU (1) | RU2181287C2 (ko) |
SG (1) | SG60073A1 (ko) |
TR (1) | TR199700522A2 (ko) |
ZA (1) | ZA975335B (ko) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
DK1030667T3 (da) * | 1997-11-14 | 2005-06-20 | Akzo Nobel Nv | Anvendelse af mirtazapin til fremstilling af et lægemiddel til behandling af sövnapnö |
US6960577B2 (en) * | 1998-05-22 | 2005-11-01 | Eli Lilly And Company | Combination therapy for treatment of refractory depression |
US6727283B2 (en) | 1998-10-13 | 2004-04-27 | Pfizer Inc. | Sertraline oral concentrate |
US6575147B2 (en) * | 1999-02-25 | 2003-06-10 | Go-Tec | Internal combustion system adapted for use of a dual fuel composition including acetylene |
EP1178805A4 (en) * | 1999-04-19 | 2004-11-24 | Teva Pharma | NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS |
US6545149B2 (en) | 1999-04-19 | 2003-04-08 | Teva Pharmaceutical Industries Ltd. | Synthesis and crystallization of piperazine ring-containing compounds |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
BR0107721A (pt) * | 2000-01-19 | 2002-10-01 | Akzo Nobel Nv | Combinação, uso de mirtapazina e gepirona, método para o tratamento de depressão ou de um distúrbio relacionado em um indivìduo de uma espécie vertebrada, e, kit de paciente que contém meios para a administração de doses unitárias dosadas |
AU2002212888A1 (en) * | 2000-11-01 | 2002-05-15 | Respiratorius Ab | Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4) |
US6399310B1 (en) | 2001-02-12 | 2002-06-04 | Akzo Nobel N.V. | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
DE60224078T2 (de) * | 2001-02-12 | 2008-12-04 | N.V. Organon | Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind. |
US20030105082A1 (en) * | 2001-12-03 | 2003-06-05 | Murphy Greer Marechal | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
MXPA04009123A (es) * | 2002-03-21 | 2005-09-08 | C Hinz Martin | Tecnologia de optimizacion del segmento del sistema de serotonina y catecolamina. |
US20090311795A1 (en) * | 2002-03-21 | 2009-12-17 | Hinz Martin C | Bilateral control of functions traditionally regulated by only serotonin or only dopamine |
US20070293571A1 (en) * | 2006-06-08 | 2007-12-20 | Hinz Martin C | Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes |
AR042806A1 (es) * | 2002-12-27 | 2005-07-06 | Otsuka Pharma Co Ltd | Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo |
CN1726039B (zh) * | 2002-12-27 | 2010-08-18 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
EP1603448A4 (en) * | 2003-02-21 | 2007-12-05 | Martin C Hinz | SEROTONIN AND CATECHOLAMINE SYSTEM SEGMENT OPTIMIZATION TECHNOLOGY |
TW200502222A (en) * | 2003-04-02 | 2005-01-16 | Novartis Ag | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
US7375111B2 (en) | 2003-04-29 | 2008-05-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
US20050234093A1 (en) * | 2003-06-25 | 2005-10-20 | H. Lundbeck A/S | Treatment of depression and other affective disorders |
US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
WO2005023767A2 (en) | 2003-09-10 | 2005-03-17 | Brentwood Equities Ltd. | Diastereomers of 4-aryloxy-3-hydroxypiperidines |
US7713959B2 (en) * | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
TW200538100A (en) * | 2004-04-21 | 2005-12-01 | Akzo Nobel Nv | Mirtazapine salts |
US20060039866A1 (en) * | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
AU2005305882B2 (en) * | 2004-11-19 | 2011-07-14 | Merck Sharp & Dohme B.V. | Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression |
EP2135603B1 (en) | 2005-11-22 | 2013-01-02 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
TW200829235A (en) | 2006-11-09 | 2008-07-16 | Orexigen Therapeutics Inc | Methods for administering weight loss medications |
KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
CN101332193B (zh) * | 2007-06-29 | 2012-12-12 | 杭州民生药业有限公司 | 一种马来酸氟伏沙明药物组合物的制备方法 |
EP2303025A4 (en) | 2008-05-30 | 2012-07-04 | Orexigen Therapeutics Inc | METHOD FOR TREATING DIGITAL FAT SWITCHES |
WO2010143628A1 (ja) | 2009-06-09 | 2010-12-16 | 住友重機械工業株式会社 | ハイブリッド式ショベル及びその制御方法 |
KR101414012B1 (ko) * | 2009-11-13 | 2014-07-01 | 주식회사 녹십자 | 아릴피페라진-함유 퓨린 유도체 및 그의 용도 |
MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
CN102000334B (zh) * | 2010-10-15 | 2012-02-22 | 北京大学 | 用于治疗抑郁症的复方制剂 |
RU2475235C2 (ru) * | 2011-03-15 | 2013-02-20 | Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" | Фармацевтическая композиция для профилактики и лечения депрессивных состояний |
TWI636784B (zh) * | 2011-04-05 | 2018-10-01 | 大塚製藥股份有限公司 | 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組,以及彼之用途 |
EP4104824A1 (en) | 2012-06-06 | 2022-12-21 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
AU8770282A (en) * | 1981-08-27 | 1983-03-03 | Shaun R. Coughlin | Composition for the treatment of atherosclerosis |
US4940585A (en) * | 1989-02-17 | 1990-07-10 | Hapworth William E | Method for the treatment of nicotine withdrawal syndrome |
US5208261A (en) * | 1989-12-06 | 1993-05-04 | Akzo N.V. | Stabilized solutions of psychotropic agents |
ATE99943T1 (de) * | 1989-12-06 | 1994-01-15 | Akzo Nv | Psychotropische wirkstoffe enthaltende stabilisierte loesungen. |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
BR9812615A (pt) * | 1997-10-03 | 2000-08-01 | Cary Medical Corp | Composições farmacêutica para tratar vìcio de tabaco ou vìcio de nicotina, para aliviar os sintomas da abstinência de nicotina ou para facilitar a cessação de fumar, para tratar vìcio de cocaìna e efeitos da abstinência associados, para tratar dependência alcoólica e efeitos da abstinência associados, e, processos para tratar vìcio de tabaco ou vìcio de nicotina, para aliviar os sintomas de abstinência de nicotina ou para facilitar a cessação de fumar, para tratar vìcio de cocaìna e efeitos da abstinência associados e, para tratar dependência alcoólica e efeitos da abstinência associados |
-
1997
- 1997-06-13 IL IL12107697A patent/IL121076A/xx not_active IP Right Cessation
- 1997-06-16 US US08/876,346 patent/US5977099A/en not_active Expired - Fee Related
- 1997-06-16 SG SG1997002068A patent/SG60073A1/en unknown
- 1997-06-17 ZA ZA9705335A patent/ZA975335B/xx unknown
- 1997-06-17 CZ CZ19971870A patent/CZ290691B6/cs not_active IP Right Cessation
- 1997-06-17 DK DK97201853T patent/DK0813873T3/da active
- 1997-06-17 NZ NZ328113A patent/NZ328113A/en unknown
- 1997-06-17 PT PT97201853T patent/PT813873E/pt unknown
- 1997-06-17 AT AT97201853T patent/ATE213159T1/de not_active IP Right Cessation
- 1997-06-17 ES ES97201853T patent/ES2172744T3/es not_active Expired - Lifetime
- 1997-06-17 DE DE69710390T patent/DE69710390T2/de not_active Expired - Fee Related
- 1997-06-18 RU RU97110083/14A patent/RU2181287C2/ru not_active IP Right Cessation
- 1997-06-18 NO NO19972816A patent/NO313177B1/no unknown
- 1997-06-18 KR KR1019970025307A patent/KR100481254B1/ko not_active IP Right Cessation
- 1997-06-18 PL PL97320628A patent/PL188520B1/pl not_active IP Right Cessation
- 1997-06-18 CA CA002208199A patent/CA2208199C/en not_active Expired - Fee Related
- 1997-06-18 BR BR9703624A patent/BR9703624A/pt not_active Application Discontinuation
- 1997-06-18 HU HU9701068A patent/HU225534B1/hu not_active IP Right Cessation
- 1997-06-19 AR ARP970102687A patent/AR007609A1/es active IP Right Grant
- 1997-06-19 TR TR97/00522A patent/TR199700522A2/xx unknown
- 1997-06-19 ID IDP972117A patent/ID17051A/id unknown
- 1997-06-19 AU AU26129/97A patent/AU727851B2/en not_active Ceased
- 1997-06-19 CN CN97115549A patent/CN1132581C/zh not_active Expired - Fee Related
- 1997-06-19 JP JP16257697A patent/JP4925074B2/ja not_active Expired - Fee Related
-
1998
- 1998-06-16 HK HK98105337A patent/HK1006081A1/xx not_active IP Right Cessation
-
2008
- 2008-12-12 JP JP2008317326A patent/JP2009137970A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR980000447A (ko) | 미르타자핀과 하나 이상의 선택적인 세로토닌 재이용 저해제로 이루어진 약학 조성물 | |
RU97110083A (ru) | Комбинация, фармацевтическая композиция, способ лечения, использование и упаковка | |
RU2009113038A (ru) | Комбинированная лекарственная терапия для лечения ожирения | |
UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
AR023715A1 (es) | Composicion farmaceutica para un sujeto que necesita una elevacion del contenido de nad intracelular, y el uso de la misma para la manufactura de unmedicamento para aumentar las respuestas celulares protectoras al stress genotoxico en la piel | |
BR0112661A (pt) | Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica | |
BRPI0314308B8 (pt) | antagonistas de opióide, seus usos, e composição farmacêutica | |
Nelson | Augmentation strategies with serotonergic-noradrenergic combinations | |
KR920702220A (ko) | 산화적 손상에 관련된 질병을 억제하기 위한 방법 및 그 조성물 | |
ATE506059T1 (de) | Therapie zur behandlung der überaktiven blase | |
AR035158A1 (es) | Inhibidores de recaptacion de norepinefrina altamente selectivos y metodo para usar los mismos | |
ES2177084T3 (es) | Uso de derivados de benzohidrilo sulfinilo para tratar la somnolencia de origen medicamentoso. | |
TWI367751B (en) | Pharmaceutical composition comprising rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction | |
BR9813651A (pt) | Compostos antipicornavirais e métodos para o seu uso e preparação | |
BR0012951A (pt) | Agonistas de retinóides seletivos | |
AR013001A1 (es) | Derivados de la piperazina, procedimientos para prepararlos, las composiciones farmaceuticas que los contienen, su utilizacion como medicamentoy el metodo para tratar enfermedades mediadas por la taquinina. | |
ATE413177T1 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
EP1254668A3 (en) | Combination of a serotonin reuptake inhibitor and a GABA-A alpha 2/3 agonist for use in anxiety and depression | |
BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
MXPA03004288A (es) | Tratamiento de disfuncion sexual inducida por farmaco antidepresivo con apomorfina. | |
BR0013582A (pt) | Agonistas retinóides seletivos para rar | |
BR0111002A (pt) | Combinação de secretagogos do hormÈnio do crescimento e antidepressivos | |
JP2002530341A5 (ko) | ||
SE9702066L (sv) | Nytt salt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20080326 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |